N4BP3 activators encompass a variety of chemical compounds that utilize cellular signaling cascades to amplify the functional activity of this protein. Central to many of these mechanisms is the elevation of intracellular cyclic AMP (cAMP) levels, an essential secondary messenger that regulates a multitude of cellular processes. The increase in cAMP is typically achieved through the activation of adenylyl cyclase or inhibition of phosphodiesterases, enzymes responsible for cAMP synthesis and degradation, respectively. Once cAMP levels are elevated, protein kinase A (PKA), a cAMP-dependent kinase, becomes activated. PKA plays a pivotal role in the phosphorylation of a broad spectrum of substrates, including N4BP3, thereby enhancing its activity. Some activators directly stimulate adenylyl cyclase, whereas others, like certain β-adrenergic agonists, act on G protein-coupled receptors to modulate the enzyme's activity. Additionally, inhibitors of phosphodiesterase create a similar effect by preventing the breakdown of cAMP, thus sustaining the activation signal.
Another layer of regulation comes from modulators of intracellular calcium levels, which can indirectly influence N4BP3 activity. Calcium ionophores, for example, facilitate the influx of calcium ions into the cell, which can activate calcium-dependent kinases. These kinases have the potential to phosphorylate N4BP3, similar to how PKA functions in the cAMP pathway. The convergence of cAMP and calcium signaling pathways illustrates the intricate network of biochemical events that lead to the functional activation of N4BP3. The chemical compounds that target these pathways are diverse in structure and origin, but function to enhance the phosphorylation status and consequently the activity of N4BP3.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC) which can phosphorylate N4BP3, potentially increasing its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium concentration, potentially activating calcium-dependent kinases that could phosphorylate N4BP3, leading to an increase in its activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cell-permeable cAMP analog that activates PKA, potentially leading to the phosphorylation and activation of N4BP3. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A β-adrenergic agonist that elevates cAMP levels, indirectly leading to the activation of PKA and potential phosphorylation of N4BP3. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A calcium ionophore that raises intracellular calcium levels, potentially leading to the activation of calcium-dependent kinases and subsequent phosphorylation of N4BP3. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
A cAMP analog that activates PKA, potentially leading to increased phosphorylation and activation of N4BP3. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Increases cAMP levels through G protein-coupled receptor signaling, leading to PKA activation and potential phosphorylation of N4BP3. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective inhibitor of phosphodiesterase 4 (PDE4) which increases intracellular cAMP levels, leading to PKA activation and potential phosphorylation of N4BP3. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterase which increases cAMP levels, leading to PKA activation and potential phosphorylation of N4BP3. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Inhibits PDE5 leading to increased cAMP levels, which can result in PKA activation and subsequent phosphorylation of N4BP3. | ||||||